95 results
Page 2 of 5
424B2
ocg7kh5dwt 1qakzsn
12 Dec 23
Prospectus for primary offering
4:41pm
8-K
EX-99.1
mpl2ml3226c
12 Dec 23
Liquidia Announces Pricing of Public Offering of Common Stock
8:44am
8-K
EX-99.1
fqwgp r09qm
7 Nov 23
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:36am
8-K
EX-99.1
wz3ej2s 9hw957bfg
25 Sep 23
Other Events
5:00pm
8-K
EX-99.1
5zzbrdc4t z8adk39
6 Sep 23
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
4:37pm
8-K
EX-99.1
p2lqu7vtysyic2 bmm9
10 Aug 23
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:00am
8-K
EX-99.1
a1pc n0wgfsn89s1
27 Jul 23
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
6:00am
8-K
EX-99.1
zmziv0gf
24 Jul 23
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
2:58pm
8-K
EX-99.1
oa9zzqts9
28 Jun 23
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
6:02am
8-K
EX-99.2
t19wzm
4 May 23
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
zl3n8e1q
4 May 23
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
PRE 14A
t9fktnvyr0lb9dce
17 Apr 23
Preliminary proxy
5:28pm
8-K
EX-99.1
576p58k9bk9l em
3 Apr 23
Entry into a Material Definitive Agreement
4:15pm